SUBSCRIBE
SUBSCRIBE
Tristan Manalac

Tristan Manalac

Contributing Writer | News

Tristan is an independent science writer based in Metro Manila, with more than eight years of experience writing about medicine, biotech and science. Being formally trained in molecular biology, he once dreamed of collecting degrees and starting his own lab. But these days, he finds his greatest joy in a bottle of beer and a beautiful sentence. He can be reached at tristan.manalac@biospace.com, tristan@tristanmanalac.com or on LinkedIn.

Pictured: Roche Diagnostics building in California
Drug Development
Roche’s Ocrevus Achieves Near-Complete Reduction of Relapse, Lesions in MS
Data from the Phase III OCARINA II study shows the subcutaneous version of Ocrevus achieved near-complete suppression of relapses and brain lesions in relapsing or primary progressive multiple sclerosis.
April 18, 2024
 · 
2 min read
 · 
Tristan Manalac
Pictured: FDA signage at its office in Washington, DC
FDA
Teva, Alvotech Secure FDA Approval for Stelara Biosimilar with Early 2025 Launch
Teva Pharmaceuticals and Alvotech got the FDA’s greenlight for their biosimilar to Johnson & Johnson’s blockbuster Stelara, which will launch in the U.S. in February 2025.
April 18, 2024
 · 
2 min read
 · 
Tristan Manalac
Pictured: Eli Lilly's headquarters in Indianapolis
Drug Development
Most Doses of Lilly’s Zepbound and Mounjaro in Short Supply Through Q2: FDA
Nearly all doses of Eli Lilly’s highly popular weight-loss drug Zepbound and type 2 diabetes medication Mounjaro will have limited availability through the second quarter of 2024, according to the regulator.
April 18, 2024
 · 
2 min read
 · 
Tristan Manalac
Pictured: Magnetic resonance imaging scans of the brain
Drug Development
Cerevel Gets Phase III Parkinson’s Win on Heels of $8.7B AbbVie Acquisition
Cerevel Therapeutics on Thursday reported positive data from its Phase III TEMPO-3 trial, showing that tavapadon can significantly improve symptom control in patients with Parkinson’s disease.
April 18, 2024
 · 
2 min read
 · 
Tristan Manalac
Pictured: Eli Lilly's biotechnology center in San Diego, California
Drug Development
Lilly Eyes Zepbound Label Expansion After Clearing Phase III Sleep Apnea Study
With Wednesday’s readout showing symptom improvements in obstructive sleep apnea patients, Eli Lilly is preparing to file for a label expansion for its blockbuster weight-loss drug Zepbound.
April 17, 2024
 · 
2 min read
 · 
Tristan Manalac
Pictured: Illustration of antibodies attacking a nerve cell
Drug Development
Cullinan Targets Autoimmune Market, Nabs $280M in Private Placement
Cullinan Oncology, now renamed Cullinan Therapeutics, is riding the growing wave of interest in autoimmune disorders by refocusing its bispecific T cell-engager CLN-978 for systemic lupus erythematosus.
April 17, 2024
 · 
2 min read
 · 
Tristan Manalac
Pictured: Gloved hand holding a collection tube for a triglyceride test
Drug Development
Arrowhead’s Plozasiran Poised for Dyslipidemia Market, $700M in Sales by 2032: GlobalData
On the heels of a Phase IIb win, Arrowhead Pharmaceuticals’ plozasiran could fulfill a critical unmet need in dyslipidemia treatment bringing in $707 million in sales by 2032, according to data analytics firm GlobalData.
April 17, 2024
 · 
2 min read
 · 
Tristan Manalac
Pictured: 3D illustration of nerve cells being destroyed
Drug Development
Amylyx Sheds More Light on Relyvrio’s Late-Stage Trial Failure in ALS
At this week’s American Academy of Neurology annual meeting, Amylyx provided additional data from its Phase III amyotrophic lateral sclerosis study showing the full extent of Relyvrio’s failure.
April 17, 2024
 · 
2 min read
 · 
Tristan Manalac
Pictured: J&J's office in Madrid, Spain
Business
J&J Narrowly Misses Q1 Revenue on Lower-Than-Expected Stelara Sales
Despite the strong performance of its cancer portfolio, Johnson & Johnson on Tuesday reported Stelara sales of $2.45 billion in the first quarter of 2024, falling short of Wall Street expectations of $2.6 billion.
April 16, 2024
 · 
3 min read
 · 
Tristan Manalac
Pictured: 3D illustration of a short single-stranded oligonucleotide
Drug Development
Ultragenyx Eyes Pivotal Study After Mid-Stage Win in Angelman Syndrome
In a Phase I/II study, Ultragenyx’s antisense oligonucleotide GTX-102 led to significant cognitive, behavioral, sleep and gross motor improvements in patients with the rare genetic disorder Angelman syndrome.
April 16, 2024
 · 
2 min read
 · 
Tristan Manalac
Pictured: Sign above the entrance to a U.S. courthouse
Policy
Pfizer, BioNTech Get Legal Pause in Moderna’s COVID-19 Vaccine Patent Lawsuit
A federal court in Massachusetts has granted Pfizer and BioNTech’s motion to put on hold Moderna’s lawsuit over alleged patent infringement related to their COVID-19 vaccine Comirnaty.
April 16, 2024
 · 
2 min read
 · 
Tristan Manalac
Pictured: CVS Health's signage outside its office in Texas
Drug Delivery
Sandoz’s Biosimilar Skyrockets After CVS Removes AbbVie’s Humira from Formularies
Prescriptions for Sandoz’s Hyrimoz, a biosimilar version of AbbVie’s Humira, have shot up after CVS Caremark took the blockbuster arthritis treatment off its major national commercial formularies on April 1.
April 16, 2024
 · 
2 min read
 · 
Tristan Manalac
Pictured: Doctor looking at a patient's MRI brain scan
Drug Development
FDA Puts Clinical Hold on Neumora’s Schizophrenia Drug Due to Preclinical Safety Signals
Following cases of convulsions in rabbits in a preclinical study, the FDA has placed a clinical hold on Neumora Therapeutics’ Phase I schizophrenia drug candidate NMRA-266.
April 15, 2024
 · 
2 min read
 · 
Tristan Manalac
Signage outside Genentech's headquarters in Silicon Valley
Business
Genentech Walks Away From $3B Allogeneic T-Cell Pact with Adaptimmune
Roche’s Genentech subsidiary is terminating for undisclosed reasons its 2021 contract with Adaptimmune for the development of allogeneic T-cell therapeutics.
April 15, 2024
 · 
2 min read
 · 
Tristan Manalac
AbbVie's office in South San Francisco, California
Drug Development
AbbVie Touts Long-Term Efficacy of Qulipta as Preventive Migraine Treatment
AbbVie’s small molecule drug Qulipta has durable benefits and can reduce migraine frequency through 48 weeks of follow-up, according to interim Phase III data released on Friday.
April 15, 2024
 · 
2 min read
 · 
Tristan Manalac
Load More